Author(s) (name and post):	Ceri Wright, Medicines Management Care Setting Team Lead Anita Sharma, Senior Pharmacist, PCN and Place, Medicines Management
Version:	Version 2
Approval Date:	13 th November 2024 – IMOC
Review Date:	November 2026

Document Control Sheet

Title:	Covert Administration of Medicines Checklist (Care Settings)		
Electronic File Name:	C:\Users\ceri.wright\NHS\STW Medicine Management - Policies, Procedures & Guidelines\Care settings\Care home\Documents C&A		
Placement in Organisational Structure:	Medicines Management		
Consultation with stakeholders:	Medicines Management Team Care Homes Domiciliary Care Providers		
Approval Level:	IMOC		
Dissemination Date:	1st December 2024	Implementation Date:	1 st December 2024
Method of Dissemination:	Email, website, via Partners in Care		

Document Amendment History

Version No.	Date	Brief Description





Covert Administration of Medicines Checklist (Care Settings)

The purpose of this checklist is to support care settings in ensuring all the correct information is gathered and recorded to enable safe and appropriate administration of covert medicines.

Section 1: Person's details			
Name		Date of birth	
Name of Care		GP surgery	
Setting/address			

When an individual refuses their medication, covert administration must be a last resort and only considered if:

- the individual lacks capacity to make an informed decision about the medication
- reasons the individual is refusing their medicine have been fully explored and addressed
- all other options have been fully explored and attempted where appropriate

Clinicians and carers should not administer medicines to a person without their knowledge if the person has mental capacity to make decisions about their treatment and care or has not been assessed in accordance with the Mental Capacity Act 2005. You must identify the need for covert administration for each medicine prescribed. Each time new medicines are added, or the dose changed of an existing medicine, you must: 1.) Identify the need again 2.) Make and record further 'best interest' decisions.

If \square No is ticked in any of the sections below, please refer to guidance for the action to take.				
Section 2: Medications				
	Has a review (including a full medication review) taken place which included exploring the reasons for refusal, possible			
_	s e.g. administration times, and the in		•	
	ed in the review described above:			
1		5		
Name:	Designation:	Date of involvement:		
Name:	Designation:	Date of involvement:		
Section 3: Assessment of	of capacity			
Does the individual lack of	apacity to make decisions to consent	to treatment for a specific condition	(with specific	
medicines)?			☐ Yes ☐ No	
Name of person(s) who a	ssessed the capacity of the individual	to make this decision:		
Name:	Designation:	Date of assessment:		
Name:	Designation:	Date of assessment:		
Has the individual been a	ssessed in accordance with the Ment	al Capacity Act 2005?	☐ Yes ☐ No	
Section 4: Best Interest	Meeting			
	am and individual's representative m	ade a decision that covert administra	ition is the least	
•	the individual's best interest?		☐ Yes ☐ No	
	lve care staff, the health professional pr		nember or advocate,	
	ering medicines covertly is in the persor ed in best interest decision:	18 best interests. Discuss and record.		
Name of person(s) involv	ed in best interest decision.			
Name:	Designation:	Date:		
Namai	Designation	Data		
Name:	Designation:	Date:		
Add additional names as	appropriate.			





Section 5: Suitability of medicines for	covert administration		
Have all medicines been checked for suitability for covert administration by a pharmacist? SPS provide some guidance. The pharmacist will need an SPS account: https://www.sps.nhs.uk/articles/covert-administration-of-medicines-in-adults-pharmaceutical-issues/			
Name of pharmacy professional consu	lted:		
Name: De	esignation:	Date:	
Section 6: Records			
Has the decision to administer medicate date of decision been recorded in the in the interpretation between the decision been recorded in the interpretation between the decision been recorded in the interpretation between the decision to administer medicate date of decision been recorded in the interpretation between the decision between			t decision and □ Yes □ No
Has the decision to administer medical date of decision been recorded in the i			t decision and ☐ Yes ☐ No
Date sent:			
Has an application been made to include Safeguard (DoLS)?	de covert administration as a co	ndition of the Deprivation of	Liberty ☐ Yes ☐ No
Method used:		Date:	
Do care staff have written, accessible of for administering the medicines covert Date advice received:	-	-	orrect method
Section 7: Review			
Has a date for review of continued nee Date of medicines review for covert ad		n agreed?	☐ Yes ☐ No
Section 8: Additional notes:			
Please add/attach any additional inform	mation:		
Section 9: Checklist completion:			
Name of person completing checklist:			
Signature:	Designation:	Date:	
A copy of this checklist should be held	within the individual's care pla	ın.	

In all cases please read, and follow the full guidance:

- CQC guidance for providers
 - https://www.cqc.org.uk/guidance-providers/adult-social-care/covert-administration-medicines
- CQC myth busters for GPs
 - $\underline{https://www.cqc.org.uk/guidance-providers/gps/gp-mythbusters/gp-mythbuster-96-covert-administration-medicines}$
- NICE A quick guide for care home managers and home care managers
 - https://www.nice.org.uk/about/nice-communities/social-care/quick-guides/giving-medicines-covertly
- Presquipp Guidance for Covert Administration? <u>PrescQIPP Bulletin 269: Care homes covert administration</u>
- Deprivation of Liberty Safeguards (DoLS) at a glance





Flow Chart for Covert Process (Acknowledgement to Lancashire Safeguarding Adult Board)

1.Background

Covert administration is when medicines are administered in a disguised format without the knowledge or consent of the person receiving them, for example, in food or in a drink.

Clinicians and carers should not administer medicines to a person without their knowledge if the person has mental capacity to make decisions about their treatment and care.

Consideration must be given to all suitable alternatives which must be attempted before covert administration is considered.

Covert administration can only be considered where the person has been deemed to lack capacity to consent to that specific treatment under the Mental Capacity Act (MCA). A person's wishes, feelings and belief's must be considered.

7. Questions to consider

- Have you followed the principles of the MCA and consulted the MCA Code of Practice?
- Covert medication is considered a restrictive practice and must be recorded in the Prescribers records and person's care records.
- If the individual is subject to a DoL order or COPDoL the supervisory body must be notified.
- 4. Staff must be skilled and competent in administration of covert medication.
- Consider using the Covert Administration of Medicines Checklist (Care Settings).

2. Why it matters?

A decision to administer medication covertly is very serious and should be made within the legal framework of the MCA, in addition to complying with organisational and professional bodies', guidance and policies.

A decision to administer medication covertly should never be taken in isolation and must always include a Prescriber, a Pharmacy Adviser, the people administering the medication and other people interested in the person's welfare. Further guidance on Deprivation of liberty safeguards can be found here.

Covert Medication Steps

1-7

6. What to do?

- 1. Request a medication review via the Prescriber.
- 2. Assess and document the person's mental capacity in relation to administration of covert medication.
- 3. Undertake formal best interest (BI) decision making process, including consultation of relevant people.

 Consider if there is an ADRT or LPA for health and welfare.
- 4. Document BI decision and record clearly with rationale in care plan.

3. Information

Covert administration of medication should never be considered as routine.

It is only appropriate for medication that is essential to control or prevent significant symptoms.

The Prescriber must consider all other valid alternatives for achieving the same treatment outcome.

Consideration must identify all suitable alternatives and they must be attempted before covert administration is considered.

4. Covert administration must be used for as short a time as possible. The person should regularly be offered the medication overtly to establish if the potential for compliance has changed.

The necessity of covert medication should be regularly reviewed.

All decisions should be made in the person's best interests using the MCA. Due to the significantly restrictive nature of this method of medication administration the process must be documented.

5. Best interests' decision-making process should be transparent with the decision made in consultation with all relevant people and not taken by one person alone. Documentation of the decision should be made available to those involved. Find out why the person does not wish to take their medication and offer all practical alternatives, including information, advice and support.

In consultation with the Prescriber consider whether the medication can be rationalised or provided in an alternative format e.g., liquid or administered at an alternative time of the day.